Edward Litton1,2, Peter Latham3, Julia Inman4, Jingjing Luo5, Peter Allan6. 1. Intensive Care Unit, St John of God Hospital Subiaco, Perth, WA, 6009, Australia. edward.litton@health.wa.gov.au. 2. School of Medicine, University of Western Australia, Perth, WA, 6009, Australia. edward.litton@health.wa.gov.au. 3. Intensive Care Unit, Noosa Hospital, Sunshine Coast, Noosaville, QLD, 4566, USA. 4. Fiona Stanley Hospital, Perth, WA, 6150, Australia. 5. Department of Anaesthesia, Rockingham General Hospital, Perth, WA, 6000, Australia. 6. Intensive Care Unit, Fiona Stanley Hospital, Perth, WA, 6150, Australia.
Abstract
PURPOSE: Severe immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically ill patients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge. METHODS: The search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions. RESULTS: The systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71-0.94, P = 0.006, I2 = 0.0%]. The RR of SAEs and thromboembolic events for the ESA and comparator groups were similar, RR 1.11 (95% CI 0.94-1.31, P = 0.228, I2 66%) and 1.22 (95% CI 0.95-1.58, P = 0.086, I2 47%), respectively. CONCLUSIONS: In heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.
PURPOSE: Severe immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically illpatients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge. METHODS: The search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions. RESULTS: The systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71-0.94, P = 0.006, I2 = 0.0%]. The RR of SAEs and thromboembolic events for the ESA and comparator groups were similar, RR 1.11 (95% CI 0.94-1.31, P = 0.228, I2 66%) and 1.22 (95% CI 0.95-1.58, P = 0.086, I2 47%), respectively. CONCLUSIONS: In heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.
Authors: Michael Silver; Michael J Corwin; Andrea Bazan; Andrew Gettinger; Christopher Enny; Howard L Corwin Journal: Crit Care Med Date: 2006-09 Impact factor: 7.598
Authors: Fred A Luchette; Michael D Pasquale; Timothy C Fabian; Wayne K Langholff; Marsha Wolfson Journal: Am J Surg Date: 2011-12-15 Impact factor: 2.565
Authors: Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne Journal: BMJ Date: 2011-10-18
Authors: Matthew A Warner; Andrew C Hanson; Phillip J Schulte; Nareg H Roubinian; Curt Storlie; Gabriel Demuth; Ognjen Gajic; Daryl J Kor Journal: J Intensive Care Med Date: 2022-02-01 Impact factor: 2.889
Authors: Carmen Ka Man Cheung; Man Fai Law; Grace Chung Yan Lui; Sunny Hei Wong; Raymond Siu Ming Wong Journal: Acta Haematol Date: 2020-07-28 Impact factor: 2.195
Authors: Hannelore Ehrenreich; Karin Weissenborn; Martin Begemann; Markus Busch; Eduard Vieta; Kamilla W Miskowiak Journal: Mol Med Date: 2020-06-16 Impact factor: 6.354
Authors: D M Baron; M Franchini; S M Goobie; M Javidroozi; A A Klein; S Lasocki; G M Liumbruno; M Muñoz; A Shander; D R Spahn; K Zacharowski; P Meybohm Journal: Anaesthesia Date: 2020-05-06 Impact factor: 6.955